Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2165-2171

  Schulze, Kornelius ^a   Gasch, Christin ^a   Staufer, Katharina ^b   Nashan, Björn ^a   Lohse, Ansgar W ^a   Pantel, Klaus ^a   Riethdorf, Sabine ^a   Wege, Henning ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

cancer stem cells; CellSearch system; circulating tumor cells; epithelial cell adhesion molecule; hepatocellular carcinoma

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

CANCER STEM CELLS; CELLSEARCH™ SYSTEM; CIRCULATING TUMOR CELLS; EPITHELIAL CELL ADHESION MOLECULE; HEPATOCELLULAR CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84882655536     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28230     Document Type: Article

References (41)

1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5-S16.
2. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-9.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Gish RG, Marrero JA, Benson AB,. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol 2010; 6 (3 Suppl 7): 1-16.
5. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
6. El-Serag HB,. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5 Suppl 1): S27-S34.
7. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.
8. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
9. Samuel M, Chow PK, Chan Shih-Yen E, et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009: CD001199.
10. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993; 328: 1802-6.
11. Oka H, Saito A, Ito K, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378-83.
12. Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59: 1687-93.
13. Miura N, Osaki Y, Nagashima M, et al. A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol 2010; 10: 46.
14. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
15. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev 2008; 8: 755-68.
16. Terris B, Cavard C, Perret C., EpCA M, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010; 52: 280-1.
17. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 204: 1973-87.
18. Tanaka M, Okabe M, Suzuki K, et al. Mouse hepatoblasts at distinct developmental stages are characterized by expression of EpCAM and DLK1: drastic change of EpCAM expression during liver development. Mech Dev 2009; 126: 665-76.
19. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
20. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009; 27: 3303-11.
21. Lianidou ES, Mavroudis D, Sotiropoulou G, et al. What's new on circulating tumor cells? A meeting report. Breast Cancer Res 2010; 12: 307.
22. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-45.
23. Fehm T, Muller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010; 124: 403-12.
24. Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011; 17: 3783-93.
25. Fan ST, Yang ZF, Ho DW, et al. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 2011; 254: 569-76.
26. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-8.
27. Llovet JM, Burroughs A, Bruix J., Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
28. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
29. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005; 92: 1862-8.
30. Bednarz-Knoll N, Alix-Panabieres C, Pantel K,. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012; 31: 673-87.
31. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
32. Ji J, Wang XW,. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012; 39: 461-72.
33. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-71.
34. Trzpis M, McLaughlin PM, de Leij LM, et al. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171: 386-95.
35. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004; 64: 5818-24.
36. Patriarca C, Macchi RM, Marschner AK, et al. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012; 38: 68-75.
37. Baeuerle PA, Gires O., EpCA M (CD326) finding its role in cancer. Br J Cancer 2007; 96: 417-23.
38. Munz M, Baeuerle PA, Gires O,. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69: 5627-9.
39. Vora SR, Zheng H, Stadler ZK, et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717-25.
40. Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-6.
41. Jeng KS, Sheen IS, Tsai YC,. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? Am J Gastroenterol 2004; 99: 1503-9.